Zibotentan in Microvascular Angina: A Randomized, Placebo-Controlled, Crossover Trial
Primary resultResult — go to the resultBetween-treatment difference −4.26 seconds 95% CI −19.60 to 11.06Authors' conclusion
Among patients with microvascular angina, short-term treatment with a relatively high dose (10 mg daily) of zibotentan was not beneficial. Target-related adverse effects were common.
Study context
- Population
- Patients with microvascular angina103 with complete data
- Participants
- 118 patients
- Comparison
- Zibotentan vs placebo
- Primary endpoint
- Treadmill exercise duration (seconds), Bruce protocol; mean within-participant difference
Methodological detailsdouble-blind, placebo-controlled, sequential crossover, enriched for RS9349379 G allele
- Double-blind
- Placebo-controlled
- Sequential crossover
- Enriched for RS9349379 G allele
Primary result
As reported in the abstract
Between-treatment difference
−4.26 seconds
95% CI −19.60 to 11.06
P = 0.5871
Zibotentanvs Placebo
between-treatment difference −4.26 seconds (95% CI −19.60 to 11.06); P = 0.5871
Secondary outcomes
Secondary outcomes
- No improvement with zibotentan
BP and plasma ET-1
- Zibotentan reduced BP and increased plasma ET-1
Safety
Adverse events
P < 0.001
Original publication
Zibotentan in Microvascular Angina: A Randomized, Placebo-Controlled, Crossover Trial. Circulation. Published 1 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →